


# VISIBLE: GUSELKUMAB IMPACT ON PSORIATIC ARTHRITIS THROUGH WEEK 48 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PSORIASIS ACROSS ALL SKIN TONES



Alice B. Gottlieb,<sup>1</sup> Amy McMichael,<sup>2</sup> Tina Bhutani,<sup>3</sup> Olivia Choi,<sup>4</sup> Katelyn Rowland,<sup>4</sup> Theodore Alkousakis,<sup>4</sup> Jessica Vasquez,<sup>4</sup> Tony Ma,<sup>4</sup> Soumya D. Chakravarty,<sup>4,5</sup> Daphne Chan,<sup>4</sup> Stacey Fitch,<sup>4</sup> Andrea Nguyen,<sup>6</sup> Seemal R. Desai,<sup>7</sup> Andrew Alexis, Joseph F. Merola

<sup>1</sup>Icahn School of Medicine at Mt Sinai, New York, NY, USA; <sup>2</sup>Wake Forest University School of Medicine, Philadelphia, PA, USA; <sup>3</sup>Synergy Dermatology, San Francisco, CA, USA; <sup>3</sup>Synergy Dermatology, San Francisco, CA, USA; <sup>4</sup>Johnson & Johnson, Horsham and Spring House, PA, USA; <sup>5</sup>Drexel University College of Medicine, Philadelphia, PA, USA; <sup>1</sup>Drexel University College of Medicine, Philadelphia, PA, USA; <sup>2</sup>Drexel University College of Medicine, Philadelphia, PA, USA; <sup>3</sup>Drexel University College of Medicine, Philadelphia, PA, USA; <sup>4</sup>Dohnson, PA, USA; <sup>5</sup>Drexel University College of Medicine, Philadelphia, Philadelphia, Philadelphia, Philadelphia, P <sup>6</sup>First OC Dermatology, Fountain Valley, CA, USA; <sup>7</sup>UT Southwestern Medical Center and Innovative Dermatology, Plano, TX, USA; <sup>8</sup>Weill Cornell Medicine, New York, NY, USA; <sup>9</sup>UT Southwestern Medical Center, Dallas, TX, USA

### BACKGROUND



VISIBLE is an ongoing Phase 3b study evaluating the efficacy and safety of guselkumab (GUS) in participants with moderate-to-severe plaque psoriasis (PsO) across all skin tones




Cohort A enrolled participants with predominantly moderate-to-severe plaque PsO, and Cohort B enrolled participants with predominantly moderate-to-severe scalp PsO




VISIBLE participants were evaluated for psoriatic arthritis (PsA) at screening; PsA was identified based on a rheumatologist-confirmed diagnosis of PsA or a Psoriasis Epidemiology Screening Tool (PEST) score ≥3


## OBJECTIVE/METHODS

This Week 48 post hoc analysis evaluates efficacy and patient-reported outcomes with GUS treatment in all VISIBLE participants with PsA at baseline (n=61; 29.8%)<sup>a</sup>




≥1 plaque outside of the scalp







 Mean baseline data reflect moderate symptoms and impacts of PsA based on PsAID-12 scores, and extensive skin and scalp disease

At baseline, 29.8% (61/205) of VISIBLE participants had PsA





At Week 16, mean change from baseline in PsAID-12 was greater with GUS vs PBO, and mean PsAID-12 improvement with GUS exceeded the MCII threshold of -3.0, which further improved through Week 48



Symptom Score: PBO=Placebo: PsA=Psoriatic arthritis: PsAID-12=Psoriatic Arthritis Impact of Disease-12


Genzyme; has received royalties from Elsevier, Springer, Wiley-Blackwell, and Wolters Kluwer Health; a

## At Week 48, more than 60% of GUS-treated participants with PsA and baseline PsAID-12 scores of >3.95

RESULTS

and ≥3.0, respectively, achieved PASS and MCII






PASS- score of <3 95 FST=Fitznatrick Skin Type: GUS=Guselkumab: LS=Least squares: MCII=Minimal clinically important improvement; PASS=Patient Acceptable Symptom Score; PBO=Placebo;

#### GUS treatment provided meaningful improvements across all PsAID-12 domains


#### Figure 5. Improvements in PsAID-12 Component Scores From Baseline to Week 48 Among GUS-Treated Participants and Week 16 PBO→GUS Crossover Participants<sup>e</sup>



Efficacy Analysis Set: participants with PsA at baseline. Δ=Mean change from baseline to Week 48. Participants who met treatment failure rules (discontinued study agent due to lack of efficacy, r initiated a prohibited psoriasis treatment prior to Week 16) were assigned a change from baseline=0. For participants who were randomized to placebo at Week 0, only those participants who crossed over to guselkumab at or after Week 16 were included in Week 48 analysis. GUS=Guselkumab; PBO=Placebo; PsA=Psoriatic arthritis; PsAID-12=Psoriatic Arthritis

### At Week 16, 72% and 60% of GUS-treated participants with PsA at screening achieved the co-primary endpoints of IGA 0/1 and PASI 90, respectively, and >40% had complete skin clearance


Figure 6. Achievement of Skin Efficacy Endpoints Through Week 48 Among Participants With PsA at Screening and Baseline IGA ≥2 and BSA ≥3%<sup>f</sup>



considered nonresponders. BSA=Body surface area; IGA=Investigator's Global Assessment; GUS=Guselkumab; PASI=Psoriasis Area and Severity Index: PBO=Placebo: PsA=Psoriatic arthritis.


At Week 48, mean percent improvements from baseline in BSA and PASI were above 92% for GUS-treated participants with PsA at screening<sup>g</sup>






PASI=Psoriasis Area and Severity Index: PBO=Placebo; PsA=Psoriatic arthritis.

#### Figure 8. Participant Who Achieved IGA 0/1 and PASI 90 at Week 16 and at Week 48



#### Figure 9. Participants Who Achieved IGA 0 and PASI 100 (Complete Clearance) at Week 16 and at Week 48



### CONCLUSIONS

At baseline, the majority of VISIBLE study participants with PsA had PsAID-12 scores above the PASS threshold, indicating the need for improved PsA control

After only 3 GUS doses, ~60% of these participants achieved clinically meaningful improvements in their PsA symptoms and health-related quality of life; these improvements continued and were maintained through Week 48

Consistent with the overall VISIBLE population, the majority of GUS-treated participants with PsA achieved notably clearer skin as assessed by IGA, PASI, and BSA measures; the VISIBLE study is

 servest as a consultant for Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, and UCB. OC, KR, TA, JV, TM, SDC, DC, and SF are employees and stockholders of Johnson. And Incyte, Isola Bristol Myers Squibb, Dermira, Bristol Myers Squibb, Eli Lilly, Ianssen, LEO Pharma, Mayne, Novartis, Ortho-Dermatologics, Pfizer, Regeneron, She has served as a speaker, investigator, and Ico Pharma, Incyte, Isola Bristol Myers Squibb, Dermira, Bristol Myers Squibb, Eli Lilly, Ianssen, LEO Pharma, and UCB. OC, KR, TA, JV, TM, SDC, DC, and SF are employees and stockholders of Johnson. And Ico Pharma, Incyte, Isola Bristol Myers Squibb, Eli Lilly, Ianssen, LEO Pharma, Incyte, Isola Bristol Myers Squibb, Dermira, Incyte, Isola Bristol Myers Squibb, Eli Lilly, Ianssen, LEO Pharma, Incyte, Isola Bristol Myers Squibb, Eli Lilly, Ianssen, Ico Pharma, Incyte, Isola Bristol Myers Squibb, Eli Lilly, Ianssen, Ico Pharma, Incyte, Isola Bristol Myers Squibb, Isola Br Enistot News Squibb, Cara, Castle, Dermavant, Eli Lilly, EPI, Galderma, Hos received on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served on an advisory board or consulted for Abovie, American, UCB, and VisualDx; has served or consulted for Abovie, American, UCB, and VisualDx; has served or consulted for Abovie, American, UCB, and VisualDx; has served or consulted for Abovie, American, UCB, and VisualDx; has served or consulted for Abovie, American, UCB, and VisualDx; has served or consulted for Abovie, American, UCB, and VisualDx; has served or consulted for Abovie, American, UCB, and VisualDx; has served or consulted for Abovie, American, UCB, and VisualDx; has served or consulted for Abovie, American, UCB, and VisualDx; has been advisory and VisualDx; and VisualDx and VisualDx and VisualDx and Vi